These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11377359)

  • 1. Effect of eptifibatide on coronary flow reserve following coronary stent implantation (an ESPRIT substudy). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy.
    Gibson CM; Cohen DJ; Cohen EA; Lui HK; Murphy SA; Marble SJ; Kitt M; Lorenz T; Tcheng JE
    Am J Cardiol; 2001 Jun; 87(11):1293-5. PubMed ID: 11377359
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.
    ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy
    Lancet; 2000 Dec; 356(9247):2037-44. PubMed ID: 11145489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin.
    Cohen DJ; O'Shea JC; Pacchiana CM; Levine G; Sarembock I; Slater J; Conn E; Smith J; Tcheng JE;
    Am J Cardiol; 2002 Jan; 89(1):61-4. PubMed ID: 11779525
    [No Abstract]   [Full Text] [Related]  

  • 4. Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; results from the ESPRIT trial.
    Dery JP; Campbell ME; Mathias J; Pieper KS; Harrington RA; Madan M; Gibson CM; Tolleson TR; O'Shea JC; Tcheng JE;
    Catheter Cardiovasc Interv; 2007 Jul; 70(1):43-50. PubMed ID: 17203469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic use of intravenous eptifibatide in patients undergoing percutaneous coronary intervention: acute coronary syndromes and elective stenting.
    Granada JF; Kleiman NS
    Am J Cardiovasc Drugs; 2004; 4(1):31-41. PubMed ID: 14967064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Peterson JG; Topol EJ; Roe MT; Sapp SK; Lincoff AM; Deckers JW; Blackstone EH; Harrington RA; Califf RM; Lauer MS
    Am J Cardiol; 2001 Mar; 87(5):532-6. PubMed ID: 11230834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effects of eptifibatide in planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial).
    Reddan DN; O'Shea JC; Sarembock IJ; Williams KA; Pieper KS; Santoian E; Owen WF; Kitt MM; Tcheng JE
    Am J Cardiol; 2003 Jan; 91(1):17-21. PubMed ID: 12505565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial.
    Puma JA; Banko LT; Pieper KS; Sacchi TJ; O'Shea JC; Dery JP; Tcheng JE
    J Am Coll Cardiol; 2006 Feb; 47(4):715-8. PubMed ID: 16487833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and methodology of the ESPRIT trial: evaluating a novel dosing regimen of eptifibatide in percutaneous coronary intervention.
    O'shea JC; Madan M; Cantor WJ; Pacchiana CM; Greenberg S; Joseph DM; Kitt MM; Lorenz TJ; Tcheng JE
    Am Heart J; 2000 Dec; 140(6):834-9. PubMed ID: 11099985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stent parameters predict major adverse clinical events and the response to platelet glycoprotein IIb/IIIa blockade: findings of the ESPRIT trial.
    Tcheng JE; Lim IH; Srinivasan S; Jozic J; Gibson CM; O'Shea JC; Puma JA; Simon DI
    Circ Cardiovasc Interv; 2009 Feb; 2(1):43-51. PubMed ID: 20031692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial.
    Fung AY; Saw J; Starovoytov A; Densem C; Jokhi P; Walsh SJ; Fox RS; Humphries KH; Aymong E; Ricci DR; Webb JG; Hamburger JN; Carere RG; Buller CE
    J Am Coll Cardiol; 2009 Mar; 53(10):837-45. PubMed ID: 19264239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac tamponade following stent implantation with adjuvant platelet IIb/IIIa receptor inhibitor administration.
    Bottner RK; Hardigan KR
    Cathet Cardiovasc Diagn; 1997 Apr; 40(4):380-2. PubMed ID: 9096940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary percutaneous coronary angioplasty with and without eptifibatide in ST-segment elevation myocardial infarction: a safety and efficacy study of integrilin-facilitated versus primary percutaneous coronary intervention in ST-segment elevation myocardial infarction (ASSIST).
    Le May MR; Wells GA; Glover CA; So DY; Froeschl M; Marquis JF; O'Brien ER; Turek M; Thomas A; Kass M; Jadhav S; Labinaz M
    Circ Cardiovasc Interv; 2009 Aug; 2(4):330-8. PubMed ID: 20031736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal antiplatelet therapy during percutaneous coronary interventions includes glycoprotein IIb/IIIa inhibitors just eliminate the infusion.
    Mahmud E; Prasad A
    J Am Coll Cardiol; 2009 Mar; 53(10):846-8. PubMed ID: 19264240
    [No Abstract]   [Full Text] [Related]  

  • 15. Eptifibatide: a pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes.
    Plosker GL; Ibbotson T
    Pharmacoeconomics; 2003; 21(12):885-912. PubMed ID: 12908844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of aspirin and clopidogrel response on myonecrosis after percutaneous coronary intervention: a BRIEF-PCI (Brief Infusion of Intravenous Eptifibatide Following Successful Percutaneous Coronary Intervention) trial substudy.
    Saw J; Densem C; Walsh S; Jokhi P; Starovoytov A; Fox R; Wong G; Buller C; Ricci D; Mancini GB; Fung A
    JACC Cardiovasc Interv; 2008 Dec; 1(6):654-9. PubMed ID: 19463380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomized placebo-controlled study.
    Indian Heart J; 2001; 53(3):376. PubMed ID: 11516048
    [No Abstract]   [Full Text] [Related]  

  • 18. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of high-dose intravenous eptifibatide as an adjunct to internal carotid artery angioplasty and stent placement: a prospective registry.
    Qureshi AI; Siddiqui AM; Hanel RA; Xavier AR; Kim SH; Kirmani JF; Boulos AS; Hopkins LN
    Neurosurgery; 2004 Feb; 54(2):307-16; discussion 316-7. PubMed ID: 14744276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eptifibatide: a review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention.
    Curran MP; Keating GM
    Drugs; 2005; 65(14):2009-35. PubMed ID: 16162023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.